Having mature and sustainable RWD insight and evidence-generating capabilities has quickly become a necessity for pharma companies, with obvious upsides. Drug development is a complex, scientific process, and the experience of highly educated experts plays a major role in decision-making. Shifting from this well-credentialed, experience-based decision-making model to a data-driven model requires a dramatic organizational shift. Many companies have begun this significant organizational shift, which requires trust-building and change management, by making big investments in data sources, partnerships and technology. While the level of investment is a great sign, none of these are a recommended first or only step. In this article, ZS experts share five key steps to developing a successful RWE capability.